Additionally, the potential benefits of neoadjuvant PD-1/PD-L1 inhibitors in resectable HNSCC have been explored, showing promising results in improving outcomes for patients undergoing surgery, showing the need for continued exploration of the tumor microenvironment to advance therapeutic strategies and improve patient outcomes [20, 21]. This evidence concerns the gene CD274 and neoplasm.